The Journal of Thoracic and Cardiovascular Surgery
Volume 137, Issue 5 , Pages 1249-1257 , May 2009

Long-acting oral phosphodiesterase inhibition preconditions against reperfusion injury in an experimental lung transplantation model

  • Eric S. Weiss, MD

      Affiliations

    • Division of Cardiac Surgery, Department of Surgery, The Johns Hopkins Medical Institutions, Baltimore, Md
    • ,
  • Hunter C. Champion, MD, PhD

      Affiliations

    • Division of Cardiology, Department of Medicine, The Johns Hopkins Medical Institutions, Baltimore, Md
    • ,
  • Jason A. Williams, MD

      Affiliations

    • Division of Cardiac Surgery, Department of Surgery, The Johns Hopkins Medical Institutions, Baltimore, Md
    • ,
  • William A. Baumgartner, MD

      Affiliations

    • Division of Cardiac Surgery, Department of Surgery, The Johns Hopkins Medical Institutions, Baltimore, Md
    • ,
  • Ashish S. Shah, MD

      Affiliations

    • Division of Cardiac Surgery, Department of Surgery, The Johns Hopkins Medical Institutions, Baltimore, Md
    • Corresponding Author InformationAddress for reprints: Ashish S. Shah, MD, Assistant Professor of Surgery, Division of Cardiac Surgery, The Johns Hopkins Hospital, Blalock 618, 600 N. Wolfe St, Baltimore, MD 21287.

Received 13 May 2008 ,Revised 25 November 2008 ,Accepted 30 December 2008.

References 

  1. Christie JD, Bavaria JE, Palevsky HI, Litzky L, Blumenthal NP, Kaiser LR, et al. Primary graft failure following lung transplantation. Chest. 1998;114:51–60
  2. King RC, Binns OA, Rodriguez F, Kanithanon RC, Daniel TM, Spotnitz WD, et al. Reperfusion injury significantly impacts clinical outcome after pulmonary transplantation. Ann Thorac Surg. 2000;69:1681–1685
  3. Granton J. Update of early respiratory failure in the lung transplant recipient. Curr Opin Crit Care. 2006;12:19–24
  4. Whitson BA, Prekker ME, Herrington CS, Whelan TP, Radosevich DM, Hertz MI, et al. Primary graft dysfunction and long-term pulmonary function after lung transplantation. J Heart Lung Transplant. 2007;26:1004–1011
  5. Whitson BA, Nath DS, Johnson AC, Walker AR, Prekker ME, Radosevich DM, et al. Risk factors for primary graft dysfunction after lung transplantation. J Thorac Cardiovasc Surg. 2006;131:73–80
  6. de Perrot M, Liu M, Waddell TK, Keshavjee S. Ischemia-reperfusion–induced lung injury. Am J Respir Crit Care Med. 2003;167:490–511
  7. Daud SA, Yusen RD, Meyers BF, Chakinala MM, Walter MJ, Aloush AA, et al. Impact of immediate primary lung allograft dysfunction on bronchiolitis obliterans syndrome. Am J Respir Crit Care Med. 2007;175:507–513
  8. Ng CS, Wan S, Arifi AA, Yim AP. Inflammatory response to pulmonary ischemia-reperfusion injury. Surg Today. 2006;36:205–214
  9. Vural KM, Oz MC. Endothelial adhesivity, pulmonary hemodynamics and nitric oxide synthesis in ischemia–reperfusion. Eur J Cardiothorac Surg. 2000;18:348–352
  10. Schutte H, Witzenrath M, Mayer K, Weissmann N, Schell A, Rosseau S, et al. The PDE inhibitor zaprinast enhances NO-mediated protection against vascular leakage in reperfused lungs. Am J Physiol. 2000;279:L496–L502
  11. Featherstone RL, Chambers DJ, Kelly FJ. Comparison of phosphodiesterase inhibitors of differing isoenzyme selectivity added to St. Thomas' hospital cardioplegic solution used for hypothermic preservation of rat lungs. Am J Respir Crit Care Med. 2000;162(3 Pt 1):850–856
  12. Kass DA, Takimoto E, Nagayama T, Champion HC. Phosphodiesterase regulation of nitric oxide signaling. Cardiovasc Res. 2007;75:303–314
  13. Masson P, Lambert SM, Brown M, Shabsigh R. PDE-5 inhibitors: current status and future trends. Urol Clin North Am. 2005;32:511–525viii
  14. Porst H. IC351 (tadalafil, Cialis): update on clinical experience. Int J Impot Res. 2002;14(Suppl. 1):S57–S64
  15. Shabsigh R, Seftel AD, Rosen RC, Porst H, Ahuja S, Deeley MC, et al. Review of time of onset and duration of clinical efficacy of phosphodiesterase type 5 inhibitors in treatment of erectile dysfunction. Urology. 2006;68:689–696
  16. Hemnes AR, Zaiman A, Champion HC. PDE5A inhibition attenuates bleomycin-induced pulmonary fibrosis and pulmonary hypertension through inhibition of ROS generation and RhoA/Rho kinase activation. Am J Physiol. 2008;294:L24–L33
  17. Bivalacqua TJ, Burnett AL, Hellstrom WJ, Champion HC. Overexpression of arginase in the aged mouse penis impairs erectile function and decreases eNOS activity: influence of in vivo gene therapy of anti-arginase. Am J Physiol Heart Circ Physiol. 2007;292:H1340–H1351
  18. Tankersley CG, Champion HC, Takimoto E, Gabrielson KL, Bedja D, Misra V, et al. Exposure to inhaled particulate matter impairs cardiac function in senescent mice. Am J Physiol Regul Integr Comp Physiol. 2008;295:R252–R263
  19. Hsu LL, Champion HC, Campbell-Lee SA, Bivalacqua TJ, Manci EA, Diwan BA, et al. Hemolysis in sickle cell mice causes pulmonary hypertension due to global impairment in nitric oxide bioavailability. Blood. 2007;109:3088–3098
  20. Eckenhoff RG, Dodia C, Tan Z, Fisher AB. Oxygen-dependent reperfusion injury in the isolated rat lung. J Appl Physiol. 1992;72:1454–1460
  21. Korom S, Hillinger S, Cardell M, Zhai W, Tan Q, Dutly A, et al. Sildenafil extends survival and graft function in a large animal lung transplantation model. Eur J Cardiothorac Surg. 2006;29:288–293
  22. Pizanis N, Milekhin V, Tsagakis K, Aleksic I, Kamler M, Jakob H. PDE-5 inhibitor donor intravenous preconditioning is superior to supplementation in standard preservation solution in experimental lung transplantation. Eur J Cardiothorac Surg. 2007;32:42–47
  23. Dutly AE, Inci I, Hillinger S, Zalunardo M, Gaspert A, Rousson V, et al. Normal gas exchange after 30-h ischemia and treatment with phosphodiesterase inhibitor PDI747. Eur J Cardiothorac Surg. 2003;24:594–600
  24. Kukreja RC, Salloum F, Das A, Ockaili R, Yin C, Bremer YA, et al. Pharmacological preconditioning with sildenafil: basic mechanisms and clinical implications. Vasc Pharmacol. 2005;42:219–232
  25. Kukreja RC, Xi L. eNOS phosphorylation: a pivotal molecular switch in vasodilation and cardioprotection?. J Mol Cell Cardiol. 2007;42:280–282
  26. Mount PF, Kemp BE, Power DA. Regulation of endothelial and myocardial NO synthesis by multi-site eNOS phosphorylation. J Mol Cell Cardiol. 2007;42:271–279
  27. Kukreja RC. Cardiovascular protection with sildenafil following chronic inhibition of nitric oxide synthase. Br J Pharmacol. 2007;150:538–540
  28. Cardella JA, Keshavjee SH, Bai XH, Yeoh JS, Granton JT, Meade MO, et al. Increased expression of nitric oxide synthase in human lung transplants after nitric oxide inhalation. Transplantation. 2004;77:886–890
  29. Liu M, Tremblay L, Cassivi SD, Bai XH, Mourgeon E, Pierre AF, et al. Alterations of nitric oxide synthase expression and activity during rat lung transplantation. Am J Physiol. 2000;278:L1071–L1081
  30. Pinsky DJ, Naka Y, Chowdhury NC, Liao H, Oz MC, Michler RE, et al. The nitric oxide/cyclic GMP pathway in organ transplantation: critical role in successful lung preservation. Proc Natl Acad Sci U S A. 1994;91:12086–12090

 Supported by the Mildred and Carmont Blitz Cardiac Research Fund, the Joyce Koons Family Cardiac Endowment Fund, the American Medical Association Foundation (AMA seed grant, E.S.W.), and the National Institutes of Health (NIH 2T32DK007713-12 ESW). Eric Weiss and Jason Williams are Irene Piccinini Investigators in Cardiac Surgery. The study was also supported in part by an American Heart Association Scientist Development Grant, a grant from the W.W.Smith Charitable Trust, a Shih-Chun Wang Young Investigator Award; a Giles F. Filley Award of the American Physiological Society; the Bernard Family Foundation, and NIHP50HL084946 (H.C.C.).

 Read at the Eighty-eighth Annual Meeting of The American Association for Thoracic Surgery, San Diego, Calif, May 10–14, 2008.

PII: S0022-5223(09)00032-4

doi: 10.1016/j.jtcvs.2008.12.040

The Journal of Thoracic and Cardiovascular Surgery
Volume 137, Issue 5 , Pages 1249-1257 , May 2009

Article Tools

* Image Usage & Resolution